Observational Study
Copyright ©The Author(s) 2019.
World J Gastrointest Oncol. May 15, 2019; 11(5): 424-435
Published online May 15, 2019. doi: 10.4251/wjgo.v11.i5.424
Table 2 Predictive factors for sorafenib response
Univariate analysisOR (95%CI)P value
Age (per 1 yr increase)1.05 (0.967-1.13)0.2660
Sex (male vs female)0.556 (0.0464-6.66)0.9950
Viral hepatitis (presence vs absence)0.527(0.123-2.27)0.6430
Albumin (per 1 g/dL decrease)6.59 (0.827-52.6)0.0750
Prothrombin time (per 1% decrease)0.977 (0.928-1.03)0.3910
Total bilirubin (per 1 mg/dL increase)0.376 (0.0378-3.74)0.4040
Platelet count (per 104/µL decrease)1.040 (0.937-1.14)0.4970
AFP (per 1 ng/mL increase)1.000 (1.000-1.00)0.5330
DCP (per 1 mAU/mL increase)1.00 (0.999-1.00)0.1100
AFP-L3% (per 1% increase)1.00 (0.996-1.01)0.4420
VEGF (per 1 pg/mL increase)0.98 (0.949-1.01)0.1950
VEGFR-2 (per 1 pg/mL increase)1.00 (0.999-1.000)0.2210
Maximum tumor size (per 1 cm increase)0.892 (0.752-1.06)0.1900
Tumor number (per 1 increase)1.11 (0.646-1.90)0.7070
PVTT (presence vs absence)0.835 (0.455-1.53)0.5590
Distant metastasis (presence vs absence)2.450 (0.64-9.37)0.1910
ADAMTS13:AC (per 1% increase)1.020 (1.0001-1.050)0.0039
VWF:Ag (per 1% increase)0.996 (0.991-1.000)0.0740
VWF:Ag/ADAMTS13:AC (per 1 increase)0.465 (0.265-0.817)0.0077
Multivariate analysis
VWF:Ag/ADAMTS13:AC (per 1 increase)0.495 (0.281-0.870)0.0147